|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: IFT80 |
Gene summary for IFT80 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | IFT80 | Gene ID | 57560 |
| Gene name | intraflagellar transport 80 | |
| Gene Alias | ATD2 | |
| Cytomap | 3q25.33 | |
| Gene Type | protein-coding | GO ID | GO:0001501 | UniProtAcc | Q9P2H3 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 57560 | IFT80 | LZE2T | Human | Esophagus | ESCC | 4.97e-03 | 3.37e-01 | 0.082 |
| 57560 | IFT80 | LZE4T | Human | Esophagus | ESCC | 2.25e-09 | 2.55e-01 | 0.0811 |
| 57560 | IFT80 | LZE20T | Human | Esophagus | ESCC | 2.87e-02 | 9.40e-02 | 0.0662 |
| 57560 | IFT80 | LZE21D1 | Human | Esophagus | HGIN | 3.55e-04 | 3.69e-01 | 0.0632 |
| 57560 | IFT80 | LZE24T | Human | Esophagus | ESCC | 5.80e-15 | 3.54e-01 | 0.0596 |
| 57560 | IFT80 | P2T-E | Human | Esophagus | ESCC | 1.52e-39 | 6.54e-01 | 0.1177 |
| 57560 | IFT80 | P4T-E | Human | Esophagus | ESCC | 7.59e-13 | 2.48e-01 | 0.1323 |
| 57560 | IFT80 | P5T-E | Human | Esophagus | ESCC | 4.07e-06 | 1.05e-01 | 0.1327 |
| 57560 | IFT80 | P8T-E | Human | Esophagus | ESCC | 2.58e-15 | 3.55e-01 | 0.0889 |
| 57560 | IFT80 | P9T-E | Human | Esophagus | ESCC | 6.41e-06 | 1.17e-01 | 0.1131 |
| 57560 | IFT80 | P10T-E | Human | Esophagus | ESCC | 9.87e-20 | 3.88e-01 | 0.116 |
| 57560 | IFT80 | P11T-E | Human | Esophagus | ESCC | 1.78e-05 | 1.67e-01 | 0.1426 |
| 57560 | IFT80 | P12T-E | Human | Esophagus | ESCC | 6.65e-11 | 1.85e-01 | 0.1122 |
| 57560 | IFT80 | P15T-E | Human | Esophagus | ESCC | 7.08e-19 | 3.61e-01 | 0.1149 |
| 57560 | IFT80 | P16T-E | Human | Esophagus | ESCC | 1.85e-21 | 3.01e-01 | 0.1153 |
| 57560 | IFT80 | P20T-E | Human | Esophagus | ESCC | 2.82e-08 | 2.01e-01 | 0.1124 |
| 57560 | IFT80 | P21T-E | Human | Esophagus | ESCC | 1.18e-10 | 1.41e-01 | 0.1617 |
| 57560 | IFT80 | P22T-E | Human | Esophagus | ESCC | 6.44e-13 | 2.73e-01 | 0.1236 |
| 57560 | IFT80 | P23T-E | Human | Esophagus | ESCC | 7.35e-08 | 1.46e-01 | 0.108 |
| 57560 | IFT80 | P24T-E | Human | Esophagus | ESCC | 2.24e-06 | 1.27e-01 | 0.1287 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:199077818 | Esophagus | HGIN | protein localization to cell periphery | 71/2587 | 333/18723 | 1.05e-04 | 2.24e-03 | 71 |
| GO:000164917 | Esophagus | HGIN | osteoblast differentiation | 50/2587 | 229/18723 | 5.88e-04 | 8.30e-03 | 50 |
| GO:003011116 | Esophagus | HGIN | regulation of Wnt signaling pathway | 65/2587 | 328/18723 | 1.53e-03 | 1.77e-02 | 65 |
| GO:001605516 | Esophagus | HGIN | Wnt signaling pathway | 83/2587 | 444/18723 | 2.27e-03 | 2.33e-02 | 83 |
| GO:019873816 | Esophagus | HGIN | cell-cell signaling by wnt | 83/2587 | 446/18723 | 2.58e-03 | 2.55e-02 | 83 |
| GO:000150316 | Esophagus | HGIN | ossification | 75/2587 | 408/18723 | 5.49e-03 | 4.49e-02 | 75 |
| GO:199077819 | Esophagus | ESCC | protein localization to cell periphery | 217/8552 | 333/18723 | 4.08e-13 | 1.88e-11 | 217 |
| GO:001605517 | Esophagus | ESCC | Wnt signaling pathway | 268/8552 | 444/18723 | 2.32e-10 | 6.58e-09 | 268 |
| GO:019873817 | Esophagus | ESCC | cell-cell signaling by wnt | 269/8552 | 446/18723 | 2.41e-10 | 6.79e-09 | 269 |
| GO:003011117 | Esophagus | ESCC | regulation of Wnt signaling pathway | 194/8552 | 328/18723 | 5.39e-07 | 7.14e-06 | 194 |
| GO:000164918 | Esophagus | ESCC | osteoblast differentiation | 140/8552 | 229/18723 | 1.63e-06 | 1.95e-05 | 140 |
| GO:000150317 | Esophagus | ESCC | ossification | 232/8552 | 408/18723 | 3.00e-06 | 3.40e-05 | 232 |
| GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
| GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
| GO:00603485 | Esophagus | ESCC | bone development | 115/8552 | 205/18723 | 1.67e-03 | 7.72e-03 | 115 |
| GO:00301788 | Esophagus | ESCC | negative regulation of Wnt signaling pathway | 97/8552 | 170/18723 | 1.81e-03 | 8.31e-03 | 97 |
| GO:00487367 | Esophagus | ESCC | appendage development | 98/8552 | 172/18723 | 1.83e-03 | 8.37e-03 | 98 |
| GO:00601737 | Esophagus | ESCC | limb development | 98/8552 | 172/18723 | 1.83e-03 | 8.37e-03 | 98 |
| GO:00355671 | Esophagus | ESCC | non-canonical Wnt signaling pathway | 45/8552 | 72/18723 | 2.97e-03 | 1.24e-02 | 45 |
| GO:19055153 | Esophagus | ESCC | non-motile cilium assembly | 39/8552 | 61/18723 | 3.08e-03 | 1.28e-02 | 39 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| IFT80 | SNV | Missense_Mutation | novel | c.1078N>G | p.Thr360Ala | p.T360A | Q9P2H3 | protein_coding | tolerated(0.14) | benign(0.001) | TCGA-A7-A5ZW-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | CR |
| IFT80 | SNV | Missense_Mutation | c.1707N>G | p.Asn569Lys | p.N569K | Q9P2H3 | protein_coding | deleterious(0.05) | benign(0.154) | TCGA-AO-A124-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
| IFT80 | SNV | Missense_Mutation | c.1462N>T | p.Leu488Phe | p.L488F | Q9P2H3 | protein_coding | deleterious(0.02) | probably_damaging(0.957) | TCGA-BH-A0C7-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR | |
| IFT80 | SNV | Missense_Mutation | c.1594N>C | p.Trp532Arg | p.W532R | Q9P2H3 | protein_coding | deleterious(0) | probably_damaging(0.909) | TCGA-D8-A1XQ-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| IFT80 | SNV | Missense_Mutation | novel | c.1729G>A | p.Asp577Asn | p.D577N | Q9P2H3 | protein_coding | tolerated(0.07) | probably_damaging(0.999) | TCGA-EW-A3E8-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | anastrozole | SD |
| IFT80 | SNV | Missense_Mutation | rs760611602 | c.2188G>A | p.Glu730Lys | p.E730K | Q9P2H3 | protein_coding | deleterious(0) | benign(0.44) | TCGA-EA-A3HQ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| IFT80 | SNV | Missense_Mutation | novel | c.698N>A | p.Thr233Asn | p.T233N | Q9P2H3 | protein_coding | deleterious(0) | possibly_damaging(0.599) | TCGA-EA-A410-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| IFT80 | SNV | Missense_Mutation | c.961C>T | p.Arg321Cys | p.R321C | Q9P2H3 | protein_coding | deleterious(0) | possibly_damaging(0.65) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | |
| IFT80 | SNV | Missense_Mutation | c.12N>C | p.Lys4Asn | p.K4N | Q9P2H3 | protein_coding | deleterious(0.02) | possibly_damaging(0.563) | TCGA-A6-4105-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD | |
| IFT80 | SNV | Missense_Mutation | c.872G>A | p.Gly291Glu | p.G291E | Q9P2H3 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A6-5660-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Ancillary | leucovorin | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |